Ocrelizumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Ocrelizumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
113
Registered trials
276
Result records
1
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Ocrelizumab can convert its Monoclonal antibody profile and CD20 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Ocrelizumab (query alias: ocrelizumab) |
|---|---|
| Modality / target | Monoclonal antibody; CD20; CD20 inhibitors, ADCC, CD20-directed cytolytic effects |
| Highest global status | Approved |
| Originator | Genentech, Inc., Biogen Idec Ltd. |
| Active developers | Roche Pharma (Schweiz) AG, Hoffmann-La Roche, Inc., Roche Registration GmbH |
The MCP disease footprint includes Multiple Sclerosis, Multiple sclerosis relapse, Multiple Sclerosis, Primary Progressive. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07609719 | Phase 4 | Not yet recruiting | 100 | Percentage of Participants With no Change or Reduction From Baseline in Number of T1 Gadolinium-enhanced (Gd+) Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) at Week 24 |
| NCT07483450 | Phase 4 | Active, not recruiting | 60 | RMS Cohort: Annualized Protocol-defined Relapse Rate |
| NCT07503340 | Phase 2 | Not yet recruiting | 25 | Peak Concentration (Cmax) of Ocrelizumab After the First SC Injection |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Efficacy and safety of a bodyweight–adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials
Phase 3; n=1613; evaluation: Negative. Reported fields: AE = 91.0 % ; AE = 94.0 % ; AE = 96.0 %
A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
Phase 3; n=1013; evaluation: not stated. Reported fields: Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12) in FAS(Median) = 133.6 weeks (95% Confidence Interval, 121.9 - 168.1); Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12) in FAS(Median) = 204.9 weeks (95% Confidence Interval, 141.1 - NA); Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12) in FAS(Median): Hazard Ratio (HR) = 0.70(95% CI, 0.57 - 0.86), P-Value = 0.0007
A Phase IIIb Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis
Phase 3; n=864; evaluation: not stated. Reported fields: Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12)(Median) = NA weeks (95% Confidence Interval, NA - NA); Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12)(Median) = NA weeks (95% Confidence Interval, NA - NA); Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12)(Median): Hazard Ratio (HR) = 0.93(95% CI, 0.73 - 1.18), P-Value = 0.5278
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Ocrelizumab addresses Multiple Sclerosis, Multiple sclerosis relapse, Multiple Sclerosis, Primary Progressive. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 1995-03-16 | Genentech and IDEC also entered into a Collaboration Agreement for C2B8 | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “A stable liquid composition of ocrelizumab”. The milestone feed surfaced a patent-application signal described as “Subcutaneous dosing of Anti-CD20/Anti-CD3 bispecific antibodies”. The milestone feed surfaced a patent-application signal described as “Dosing for treatment with Anti-CD20/Anti-CD3 bispecific antibodies”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
